

2.4. CDC and ADCC assays

KM Kohtaro Minami


Updated date: Nov 27, 2022

 An abbreviated version of this protocol was published in Molecular Genetics and Metabolism Reports in Apr 2021

Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II

DOI: 10.1016/j.ymgmr.2021.100758

Related files

 Protocol_for_ADCC.pdf



 Protocol_for_CDC.pdf



How to cite: (Readers should cite both the Bio-protocol preprint and the original research article where this protocol was used)

1. Minami, K. (2022). 2.4. CDC and ADCC assays. Bio-protocol Preprint. bio-protocol.org/prep2057.
2. Yamamoto, R., Yoden, E., Tanaka, N., Kinoshita, M., Imakiire, A., Hirato, T. and Minami, K. (2021). Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II. Molecular Genetics and Metabolism Reports 0(0). DOI: [10.1016/j.ymgmr.2021.100758](https://doi.org/10.1016/j.ymgmr.2021.100758)

Copyright: Content may be subjected to copyright.